2014
Impact of Cardiovascular Events on Change in Quality of Life and Utilities in Patients After Myocardial Infarction A VALIANT Study (Valsartan In Acute Myocardial Infarction)
Lewis EF, Li Y, Pfeffer MA, Solomon SD, Weinfurt KP, Velazquez EJ, Califf RM, Rouleau JL, Kober L, White HD, Schulman KA, Reed SD. Impact of Cardiovascular Events on Change in Quality of Life and Utilities in Patients After Myocardial Infarction A VALIANT Study (Valsartan In Acute Myocardial Infarction). JACC Heart Failure 2014, 2: 159-165. PMID: 24720924, DOI: 10.1016/j.jchf.2013.12.003.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAgedAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsBundle-Branch BlockCaptoprilDeath, Sudden, CardiacDrug Therapy, CombinationFemaleHealth StatusHeart FailureHospitalizationHumansMaleMyocardial InfarctionQuality of LifeRecurrenceStrokeSurvivorsTetrazolesTreatment OutcomeValineValsartanConceptsNonfatal CV eventsEQ-5D assessmentCV eventsVisual analog scaleEQ-5D scoresCardiovascular eventsMyocardial infarctionEQ-5DBaseline EQ-5D scoresKillip class IINonfatal cardiovascular eventsHealth-related qualityLinear mixed-effects regression modelsQuality of lifeMixed effects regression modelsVALIANT studyWorse HRQLVAS scoresEjection fractionNonfatal eventsMI survivorsAnalog scaleVALIANT trialGeneric instrumentsPatients
2008
High-risk myocardial infarction in the young: The VALsartan In Acute myocardial iNfarcTion (VALIANT) trial
Anderson RE, Pfeffer MA, Thune JJ, McMurray JJ, Califf RM, Velazquez E, White HD, Rouleau JL, Skali H, Maggioni A, Solomon SD. High-risk myocardial infarction in the young: The VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. American Heart Journal 2008, 155: 706-711. PMID: 18371480, DOI: 10.1016/j.ahj.2007.11.016.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsCardiovascular DiseasesDiabetes ComplicationsFemaleHumansHypertensionKaplan-Meier EstimateMaleMiddle AgedMortalityMultivariate AnalysisMyocardial InfarctionProportional Hazards ModelsRisk FactorsSex FactorsSmokingSurvivorsTetrazolesValineValsartanConceptsAcute myocardial infarctionAcute Myocardial Infarction trialMyocardial Infarction trialRisk factorsMyocardial infarctionHigh-risk myocardial infarctionCardiovascular event ratesInfluence of hypertensionMultivariate Cox regressionPrognostic risk factorsHistory of MICardiovascular outcomesCurrent smokersLess diabetesYounger patientsCox regressionPost-AMIAdvanced ageRelative riskYoung survivorsAge groupsHypertensionEvent ratesPatientsOutcomes
2006
Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: The VALIANT experience
Stephenson K, Skali H, McMurray JJ, Velazquez EJ, Aylward PG, Kober L, Van de Werf F, White HD, Pieper KS, Califf RM, Solomon SD, Pfeffer MA. Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: The VALIANT experience. Heart Rhythm 2006, 4: 308-313. PMID: 17341394, DOI: 10.1016/j.hrthm.2006.11.021.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsBundle-Branch BlockCaptoprilElectrocardiographyFemaleFollow-Up StudiesHeart FailureHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionPredictive Value of TestsProportional Hazards ModelsResearch DesignRisk FactorsStroke VolumeSurvival AnalysisSurvivorsTetrazolesTime FactorsTreatment OutcomeValineValsartanVentricular Dysfunction, LeftConceptsNew left bundle branch blockLeft bundle branch blockLV systolic dysfunctionHigh-risk survivorsHeart failureMyocardial infarctionBundle branch blockSystolic dysfunctionCardiovascular outcomesIndependent predictorsBranch blockLeft ventricular systolic dysfunctionLong-term cardiovascular complicationsMajor adverse cardiovascular outcomesAcute Myocardial Infarction trialBaseline ECG dataMajor cardiovascular outcomesPost-MI survivorsComposite of deathMyocardial Infarction trialVentricular systolic dysfunctionAdverse cardiovascular outcomesHigh-risk patientsLV ejection fractionLong-term outcomes